SCHEMBL2482058

SCHEMBL2482058

C[C@@H](OC(=O)[C@@H](N)CCC(N)=O)[C@H](N)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.53
BLM P54132 1/20 0.53
PMP22 Q01453 1/20 0.53
KMT2A Q03164 1/20 0.53
DPP4 P27487 2/20 0.41
DPP8 Q6V1X1 2/20 0.41
DPP9 Q86TI2 2/20 0.41
SLC1A1 P43005 4/20 0.37
SLC1A3 P43003 3/20 0.37
SLC1A2 P43004 3/20 0.37
GRM8 O00222 1/20 0.37
GRM6 O15303 1/20 0.37
GRIN2D O15399 1/20 0.37
GRIN3B O60391 1/20 0.37
GSR P00390 1/20 0.37
CYP1A2 P05177 1/20 0.37
GRIK1 P39086 1/20 0.37
GRM5 P41594 1/20 0.37
GRIA1 P42261 1/20 0.37
GRIA2 P42262 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Asparagine SCHEMBL6130108 0.93 ALOX15 (0.50) ALOX15BLMPMP22KMT2ADPP4
Cysteine SCHEMBL8071966 0.91 ALOX15 (0.49) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL1767320 0.88 CYP1A2 (0.52) ALOX15BLMPMP22KMT2ADPP4
Glutamine SCHEMBL16914546 0.88 KMT2A (0.56) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL22772958 0.83 ALOX15 (0.57) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL1964052 0.83 SLC7A5 (0.39) ALOX15BLMPMP22KMT2ASLC1A1
Glutamine SCHEMBL7696024 0.82 KMT2A (0.49) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL5964545 0.80 ALOX15 (0.52) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL7775146 0.80 ALOX15 (0.52) ALOX15BLMPMP22KMT2ADPP4
Leucine SCHEMBL6130154 0.80 SLC7A5 (0.51) DPP4DPP8DPP9SLC1A1SLC1A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3544992-A1 G-PROTEIN-COUPLED RECEPTOR INTERNAL SENSORS The Regents of The University of California (US) 2019-10-02 EP claimed
WO-2018098262-A1 G-PROTEIN-COUPLED RECEPTOR INTERNAL SENSORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-05-31 WO claimed
CN-102245208-B immunoglobulin variants and uses thereof HOFFMAN-LA ROCHE LTD. (CH) 2016-03-16 CN claimed
CN-117180432-A Use of inhibitors of oxidized ATM for the treatment of breast cancer 重庆医科大学 2023-12-08 CN disclosed
US-20230384333-A1 GPCR SCREENING METHOD TO IDENTIFY NON-HALLUCINOGENIC COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-11-30 US disclosed
CN-117015712-A GPCR screening method for identifying non-magic compound 加利福尼亚大学董事会 2023-11-07 CN disclosed
US-20230348557-A1 T cell receptors Targeting Defective DNA Repair Proteins UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2023-11-02 US disclosed
EP-4229075-A1 GPCR SCREENING METHOD TO IDENTIFY NON-HALLUCINOGENIC COMPOUNDS The Regents of the University of California (US) 2023-08-23 EP disclosed
EP-4099989-A2 T CELL RECEPTORS TARGETING DEFECTIVE DNA REPAIR PROTEINS University of Pittsburgh - Of the Commonwealth System of Higher Education (US) 2022-12-14 EP disclosed
WO-2022081631-A1 GPCR SCREENING METHOD TO IDENTIFY NON-HALLUCINOGENIC COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-04-21 WO disclosed
WO-2021158962-A2 T CELL RECEPTORS TARGETING DEFECTIVE DNA REPAIR PROTEINS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2021-08-12 WO disclosed
EP-2377881-A2 Clostridial toxin activatable clostridial toxins Allergan, Inc. (US) 2011-10-19 EP disclosed
US-20100239563-A1 PHARMACEUTICAL COMPOSITION FOR THE PROPHYLAXIS AND/OR TREATMENT OF VIRAL DISEASES LUDWIG STEPHAN 2010-09-23 US disclosed
US-20090019609-A1 Expression of Cry3B Insecticidal Protein in Plants ROMANO CHARLES P 2009-01-15 US disclosed
US-20050129694-A1 Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases LUDWIG STEPHAN (DE) 2005-06-16 US disclosed
US-6803203-B1 PROTEIN KINASES; FOR MONITORING IN VITRO ACTIVITY IN EUKARYOTIC CELLS; DRUG SCREENING; KITS BROOKHAVEN SCIENCE ASSOCIATES 2004-10-12 US disclosed
US-6803203-B1 PROTEIN KINASES; FOR MONITORING IN VITRO ACTIVITY IN EUKARYOTIC CELLS; DRUG SCREENING; KITS BROOKHAVEN SCIENCE ASSOCIATES 2004-10-12 US disclosed
US-20020034570-A1 Cheese flavoring SYMRISE GMBH & CO. KG (DE) 2002-03-21 US disclosed
US-6298858-B1 Tobacco flavoring components of enhanced aromatic content and method of providing same R. J. REYNOLDS TOBACCO COMPANY 2001-10-09 US disclosed
WO-2000028840-A1 TOBACCO FLAVORING COMPONENTS OF ENHANCED AROMATIC CONTENT AND METHOD OF PROVIDING SAME R. J. REYNOLDS TOBACCO COMPANY (US) 2000-05-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230384333-A1 GPCR SCREENING METHOD TO IDENTIFY NON-HALLUCINOGENIC COMPOUNDS HTR4, HTR6, HTR1A ALOX15 3974/4885BLM 4150/4885PMP22 1232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.